Eureka Therapeutics has developed a unique strategy for engineering T cell therapies against solid tumors.Our proprietary science platform enables the targeting of previously inaccessible intracellular antigens by engineering human antibodies against peptide-MHC complexes.Combined with our novel T cell signaling platform, ARTEMIS™, we aim to improve upon the efficacy and safety of current T cell therapies .Webmail:  www.eurekainc